Psyence Biomedical
6 hedge funds and large institutions have $625K invested in Psyence Biomedical in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 4 closing their positions.
129% more capital invested
Capital invested by funds: $273K → $625K (+$352K)
8.38% more ownership
Funds ownership: 0.23% → 8.61% (+8.4%)
25% less funds holding
Funds holding: 8 → 6 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Parallel Advisors
San Francisco,
California
|
+$1.22M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$14.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$52.6K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$45.2K |
| 3 |
VF
Virtu Financial
New York
|
-$22K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$9.99K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$7.76K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PA
1
Parallel Advisors
San Francisco,
California
| $462K | +$1.22M | +44,000 | New |
|
|
SM
2
Sabby Management
Miami Beach,
Florida
| $108K | -$52.6K | -1,901 | -37% |
|
|
AI
3
AdvisorShares Investments
Bethesda,
Maryland
| $23.7K | – | – | – |
|
|
4
Bank of America
Charlotte,
North Carolina
| $17.8K | +$14.8K | +534 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $10.4K | -$9.99K | -361 | -54% |
|
|
SFFS
6
Stonehage Fleming Financial Services
St. Helier,
Jersey
| $2.99K | – | – | – |
|
|
7
Citadel Advisors
Miami,
Florida
| – | -$45.2K | -1,512 | Closed |
|
|
VF
8
Virtu Financial
New York
| – | -$22K | -732 | Closed |
|
|
TSS
9
Two Sigma Securities
New York
| – | -$7.76K | -260 | Closed |
|
10
Morgan Stanley
New York
| – | -$41 | -1 | Closed |
|
PBM Hedge Fund Activity: Q2 2025 in Review
6 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Psyence Biomedical (PBM) for Q2 2025, worth a combined $625K — up 129% from $273K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of PBM and 2 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 0 added.
The largest buyer was Parallel Advisors, opening a new position worth an estimated $1.22M. The largest seller was Sabby Management, cutting an estimated $52.6K.
- 6 institutional investors held Psyence Biomedical (PBM) as of Q2 2025, down from 8 in Q1 2025.
- Funds reported $625K of Psyence Biomedical stock for Q2 2025, up 129% quarter-over-quarter.
- 2 funds opened new Psyence Biomedical positions in Q2 2025 and 4 closed out, a net change of -2 holders.
- The largest Psyence Biomedical buyer in Q2 2025 was Parallel Advisors, an estimated $1.22M added.
- The largest Psyence Biomedical seller in Q2 2025 was Sabby Management, an estimated $52.6K sold.
Based on aggregated 13F filings for Q2 2025.